Rising demand for safer alternatives to injections and innovations in digital integration are set to drive growth. North America, Asia-Pacific, and Europe present key regional markets.Dublin, Jan. 22, ...
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, ...
AbbVie is now one of 16 big pharma companies to sign MFN deals with the Trump administration and commit to the expansion of ...
AbbVie has joined many of its big pharma peers by signing a Most-Favoured Nation (MFN) drug pricing deal with the Trump ...
The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...
ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...
ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ...
Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...
MoonLake regains momentum after the FDA Type B meeting allows BLA submission for sonelokimab in HS without additional trials.
SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost management strategies.
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
These products are among the largest oncology biologics expected to lose exclusivity over the next five years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback